#USA #New York #Securities Class Action #Fractyl Health #GUTS Stock

Fractyl Health Investors Alerted: Urgent Class Action Information

In a surprising turn of events, shares of Fractyl Health, Inc. (NASDAQ: GUTS) have seen a drastic decline recently, prompting Levi & Korsinsky, LLP to alert shareholders about a new class action lawsuit aimed at protecting investors. The lawsuit is focused on those who purchased Fractyl securities during the period between January 13, 2025 and January 29, 2026, raising critical concerns about the company’s stock performance and transparency.

Background on Fractyl Health’s Troubling Market Performance

The woes began when Fractyl Health released data from its REMAIN-1 Midpoint Cohort study, which shook market confidence and resulted in a staggering loss of approximately 74.86% in the company's share value over just two trading sessions. On January 28, 2026, GUTS shares closed at $1.83. However, by January 30, 2026, after reporting unsatisfactory results regarding the effectiveness of their Revita treatment for maintaining weight loss, the shares plummeted to $0.46, effectively wiping out $1.37 from the stock price in just two days.

Details of the Class Action Lawsuit

Investors may now qualify to recoup losses due to the significant stock price drop caused by information that was allegedly withheld from them. The details of the class action indicate that the decline was driven by statements made on January 29, which revealed that the Revita treatment group regained weight at a rate contrasted unfavorably with initial claims. The report indicated that patients treated with Revita had a weight regain of 4.5% compared to 7.5% in the sham group, leading to a total stock drop of 68.03% in one day.

Joseph E. Levi, Esq., from Levi & Korsinsky, stressed that the drop's magnitude reflects a sharp reassessment of Revita's prospects, revealing a discrepancy between reported outcomes and actual efficacy. He emphasized that investors were entitled to this information much earlier.

Key Dates and Information for Investors

Important Deadlines:

• - Potential Lead Plaintiff Filing Deadline: October 20, 2026
• - Investors who want to be considered in this class action should act promptly.

Actions for Investors:

Shareholders should gather their brokerage records indicating purchase dates, quantities, and prices paid. This information will be crucial to determine eligibility for recovery, even for those who have already sold their shares. Interestingly, investor eligibility depends solely on purchase timing, not the current holding status of shares. Those who find themselves eligible are invited to submit their information to Levi & Korsinsky for a free assessment of potential recovery.

Conclusion

This class action highlights the importance of transparency in financial disclosures, particularly when it involves the health sector and clinical treatments. As legal proceedings unfold, investors are encouraged to stay informed and consider their options if they feel they have been misled during their investment in Fractyl Health.

For more information or to submit your inquiry, you can reach out to Joseph E. Levi, Esq., at Levi & Korsinsky by calling (212) 363-7500 or by emailing [email protected] The firm has a long-standing reputation for representing shareholders and is recognized in the ISS Top 50 for seven consecutive years. Investors wishing to recover losses need to act quickly as the time to file claims is limited.

Stay tuned for further updates on this developing story and other class action alerts as they become available.